Anthropic has confirmed a physical AI biology lab in the Bay Area, alongside a hardware standard and verified model access for pharma and life sciences teams.
Anthropic has confirmed it runs an AI biology lab in the Bay Area, where Claude helps direct physical wet-lab experiments alongside human scientists.
The disclosure lands days after Anthropic opened a hardware standard for lab robotics and a verified access programme for life sciences teams.
Image
Anthropic’s Wet Lab for AI Biology Experiments
Anthropic told TechCrunch and Reuters that it operates a wet-biology lab in the San Francisco Bay Area, where Claude models help run physical experiments rather than purely computational ones.
Eric Kauderer-Abrams, Anthropic’s Head of Life Sciences, described the facility as working the way most biotech labs do.
Some research happens in-house, Kauderer-Abrams said, while other work is carried out with external partners. He stressed that the ultimate test of a biological hypothesis still happens on the lab workbench, and confirmed Anthropic is applying that approach today.
The confirmation follows recent public comments from Anthropic chief executive Dario Amodei, who suggested AI could help cure most major diseases within five to ten years.
Closing that gap between prediction and cure requires a way to test AI-generated hypotheses physically, which is precisely what a wet lab provides.
Anthropic has been careful to state that the lab’s purpose is not drug discovery specifically. Pharmaceutical leaders will want to note that distinction closely, given how much the company’s other announcements this year point in a really different direction.
The disclosure also arrived alongside continued attention on Anthropic’s AI biosafety culture, following the widely reported resignation of an Anthropic researcher earlier in September 2026 who raised concerns about the pace of frontier AI development.
Anthropic has not linked that departure to the biology lab directly, but the timing puts both stories in front of the same audience of pharma and life sciences buyers.
For pharmaceutical leaders watching AI vendors edge closer to biology, the lab raises a more pointed question: Where does research support end, and where does drug discovery competition begin?
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."
Image
A Fast-Moving Build-out Across Life Sciences
The Anthropic wet lab did not appear on its own. It is the latest step in a run of announcements Anthropic has made across five weeks, each one expanding its reach into physical and biological science.
Taken together, they describe a company moving from software into equipment, access, and talent, three areas that used to sit firmly on the pharma side of the table.
The Model Hardware Standard
On 27 August 2026, Anthropic opened a research preview of the Model Hardware Standard, a shared specification that lets AI agents discover and operate physical devices such as microscopes, liquid handlers, and robotic arms.
Early partners, including QuEra Computing, Genentech, and the HHMI Janelia Research Campus, reported integration work dropping from weeks to hours.
QuEra's laser-lock recovery controller, built by an agent using the standard, succeeded on 99.3% of 700 trials, against a 58% baseline for manually written scripts.
Anthropic plans to open-source the standard once safety evaluations with partners are complete.
Image
The Life Sciences Verification Program
On 17 September 2026, Anthropic launched the Life Sciences Verification Program in beta, giving vetted life-science organisations access to its Mythos, Opus, and Sonnet models under safeguards built specifically for biology work.
Anthropic said it had already onboarded dozens of organisations through early access, with individual Pro and Max plan access due to follow.
The programme offers two grant types, Standard Use and High-risk Use, so that access can be scaled to how sensitive a given piece of biology work is.
The Coefficient Bio acquisition
In April 2026, Anthropic acquired Coefficient Bio, a stealth biotech startup founded by former Genentech computational biology researchers, in an all-stock deal reported at just over $400 million.
The nine-person team, which won an ICLR 2024 Outstanding Paper Award for its protein and antibody design work, joined Anthropic’s Health and Life Sciences division.
Its co-founders, Samuel Stanton and Nathan Frey, previously worked in Genentech’s Prescient Design computational biology unit, a reminder of how much pharma-trained talent is now moving directly into AI vendor organisations.
Image
Why the AI Biology Lab Sits Awkwardly Alongside Pharma Partnerships
Anthropic says the AI biology lab is not specifically for drug discovery, yet the company has expanding commercial ties to the pharmaceutical sector it says it does not want to compete with.
It has struck a joint drug discovery collaboration with Novo Nordisk, alongside relationships with numerous other pharmaceutical customers.
Anthropic has openly acknowledged the tension. The company has said it does not want to give the appearance of competing with the pharma industry, particularly given how many major customers and partners it already serves there.
That acknowledgement is itself useful information for a pharma buyer weighing how a vendor’s own commercial incentives might shift over time.
The same week the original TechCrunch report ran, Anthropic published research showing Claude designing protein binders that beat typical industry hit rates of 10 to 15%, with success rates of between 22% and 35%.
It separately reported accelerating more than 30 open-source biomolecular models by roughly four times in under four weeks.
Both results sit close to the core of drug discovery work, even as the company frames its physical lab in narrower terms.
For pharma decision-makers, the practical distinction between supporting biology and doing drug discovery may matter less when an AI vendor is building wet-lab capability, a hardware standard, and biomolecular tooling in parallel with its enterprise pharma relationships.
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Image
Factors to Consider When Assessing AI Vendors in Pharma
In order for assessment, four questions are worth raising internally before assuming an AI vendor remains a pure technology supplier.
Vendor concentration risk: If AI companies build in-house wet-lab and discovery capability, licensing partners may eventually find themselves competing with their own supplier.
Verification and access governance: The Life Sciences Verification Program’s Standard Use and High-risk Use grants will shape which teams can run sensitive biology workflows, and under what renewal terms.
Data and IP boundaries: Partnerships built on shared datasets need clear contractual lines between what trains a vendor’s model and what stays proprietary to the pharma partner.
Biosecurity oversight: Experiments directed by AI models raise governance questions that sit outside conventional software risk assessments, and regulators are likely to take a closer interest.
Competitive intelligence: Procurement and R&D teams should track a vendor’s own life sciences announcements as closely as they track its model release notes, since the two are increasingly part of the same strategy.
What the Anthropic AI Biology Lab Means for the Pharma Industry
Anthropic's AI biology lab confirms what months of announcements and speculation were signalling. The company is building physical, not just computational, capability in the life sciences, wrapped in access controls it hopes will keep pace with the risk.
Pharma leaders do not need to treat this as alarming, but they should treat it as material, and weigh it alongside the usual questions about model performance, cost, and contractual protection.
The organisations that ask these fundamental questions early will be in a stronger position to negotiate, rather than reacting once a vendor’s ambitions have already reshaped the market around them.
Pharmatica exists to translate these high-impact developments into clear strategic Insight, connecting data, governance, and market dynamics so that decision-makers can act with confidence when it matters most.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What is Anthropic's AI biology lab?
It is a physical wet-lab facility in the San Francisco Bay Area where Anthropic uses Claude to help run biology experiments, confirmed by the company to TechCrunch and Reuters in September 2026.
Is Anthropic’s biology lab used for drug discovery?
Anthropic says the lab is not specifically for drug discovery, though the company runs other research and commercial work, including a partnership with Novo Nordisk and its own protein design experiments, that touches directly on drug development.
What is the Life Sciences Verification Program?
It is a beta programme Anthropic launched on 17 September 2026 that gives vetted life-science organisations verified access to its most capable models under safeguards built for biology work.
What is the Model Hardware Standard?
It is a shared specification Anthropic opened in research preview on 27 August 2026 that lets AI agents discover and operate lab and manufacturing equipment such as microscopes, liquid handlers, and robotic arms.
Why does Anthropic’s AI biology lab matter to pharmaceutical companies?
It signals that an AI vendor several pharma companies rely on is also building physical, experimental, and drug-discovery-adjacent capability, which raises vendor risk, governance, and competitive questions worth raising directly with suppliers before contracts are renewed.
Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
Did you enjoy the content?
2
Why not support
Nicole Dale
by giving this content a like
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
What is a Continuous Improvement Mindset in Pharma Manufacturing?
A continuous improvement mindset strengthens pharma manufacturing quality. See how quality management and CGMP inspections can sustain continuous improvement.
Better Predictive Modelling for Better Drug Development
Discover how predictive modelling, QSP, AI, and systems biology creates better drug development by connecting biological evidence with better predictions.
Comments (0)